PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Montelukast - Asthma
PAD Profile : Montelukast - Asthma Important
Keywords :
Leukotriene receptor antagonists, LTRAs
Brand Names Include :
Singulair
Important Information :
https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
06 March 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Montelukast may be an appropriate first-line addition to ICS (particularly if atopy or allergic component).
Prescribe generically (the brand Singulair was assigned a BLACK traffic light status by the PCN in May 2017)
The guidelines for Asthma can be found below
Associated BNF Codes
03. Respiratory System
03.03.02. Leukotriene receptor antagonists